Literature DB >> 8972753

Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study.

E M Castellà1, A Ariza, I Ojanguren, J L Mate, X Roca, A Fernández-Vasalo, J J Navas-Palacios.   

Abstract

Alternative splicing gives rise to numerous CD44 isoforms, some of which seem to have a role in tumour metastasis. Specifically, a variant form of CD44 with sequences encoded by exon v6 (CD44v6) confers metastatic potential when transfected into a nonmetastasizing cell line of rat pancreatic adenocarcinoma. This study has investigated standard CD44 (CD44s) and CD44v6 expression immunohistochemically in 6 samples of normal pancreatic tissue, 4 of tissue affected by chronic pancreatitis, and 24 of tissue from metastasizing and nonmetastasizing pancreatic adenocarcinomas. In addition, 18 samples from lymph node or visceral metastases were included in the study. CD44s was expressed in nonneoplastic tissue and in tissue from pancreatic adenocarcinomas. In contrast, CD44v6 was not detected in any of the normal tissue or chronic pancreatitis specimens, whereas 54% of pancreatic adenocarcinomas and 55% of metastases expressed this variant exon. Although it is not clear whether CD44 isoforms containing exon v6 play a part in malignant progression in the human exocrine pancreas, it seems plausible that the expression of multiple isoforms containing this and other variant exon confers a selective advantage on pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972753     DOI: 10.1007/bf00198333

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  Lymph node involvement in carcinoma of the head of the pancreas area.

Authors:  A L Cubilla; J Fortner; P J Fitzgerald
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

2.  CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.

Authors:  R Ristamäki; H Joensuu; K O Söderström; S Jalkanen
Journal:  J Pathol       Date:  1995-07       Impact factor: 7.996

3.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

4.  Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas.

Authors:  F Gansauge; S Gansauge; A Zobywalski; C Scharnweber; K H Link; A K Nussler; H G Beger
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

5.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms.

Authors:  S B Fox; J Fawcett; D G Jackson; I Collins; K C Gatter; A L Harris; A Gearing; D L Simmons
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

6.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

7.  The significance of CD44 in human pancreatic cancer: II. The role of CD44 in human pancreatic adenocarcinoma invasion.

Authors:  M Takada; M Yamamoto; Y Saitoh
Journal:  Pancreas       Date:  1994-11       Impact factor: 3.327

8.  CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma.

Authors:  C J Rall; A K Rustgi
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

9.  Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation.

Authors:  S M Denning; P T Le; K H Singer; B F Haynes
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

10.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.

Authors:  I Stamenkovic; A Aruffo; M Amiot; B Seed
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

View more
  12 in total

1.  Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma.

Authors:  Domenico Coppola; James Helm; Msoumeh Ghayouri; Mokenge P Malafa; Hong-Gang Wang
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

2.  Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.

Authors:  Ryota Takahashi; Yoshihiro Hirata; Kosuke Sakitani; Wachiko Nakata; Hiroto Kinoshita; Yoku Hayakawa; Hayato Nakagawa; Kei Sakamoto; Yohko Hikiba; Hideaki Ijichi; Harold L Moses; Shin Maeda; Kazuhiko Koike
Journal:  Cancer Sci       Date:  2013-01-24       Impact factor: 6.716

3.  Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.

Authors:  Heike Immervoll; Dag Hoem; Ole Johnny Steffensen; Hrvoje Miletic; Anders Molven
Journal:  J Histochem Cytochem       Date:  2011-04       Impact factor: 2.479

4.  Brain metastases from pancreatic adenocarcinoma.

Authors:  Aziz Zaanan; Marie Lequoy; Bruno Landi; Astrid Lievre; Dominique Franco; Julien Taïeb
Journal:  BMJ Case Rep       Date:  2009-02-27

5.  PTEN loss accelerates KrasG12D-induced pancreatic cancer development.

Authors:  Reginald Hill; Joseph Hargan Calvopina; Christine Kim; Ying Wang; David W Dawson; Timothy R Donahue; Sarah Dry; Hong Wu
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

6.  Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma.

Authors:  T Gotoda; Y Matsumura; H Kondo; H Ono; A Kanamoto; H Kato; H Watanabe; Y Tachimori; Y Nakanishi; T Kakizoe
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

7.  Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma.

Authors:  Ardeshir Hakam; Quan Fang; Richard Karl; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

8.  Immunohistochemical analyses of E-cadherin, beta-catenin, CD44s, and CD44v6 expressions, and Ki-67 labeling index in intraductal papillary mucinous neoplasms of the pancreas and associated invasive carcinomas.

Authors:  Akira Okimura; Hiroshi Hirano; Takashi Nishigami; Shigemitsu Ueyama; Shiro Tachibana; Yoshikazu Fukuda; Koji Yamanegi; Hideki Ohyama; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2009-12-24       Impact factor: 2.309

Review 9.  Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.

Authors:  Norihiro Sato; Shiro Kohi; Keiji Hirata; Michael Goggins
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

Review 10.  The biology and role of CD44 in cancer progression: therapeutic implications.

Authors:  Chen Chen; Shujie Zhao; Anand Karnad; James W Freeman
Journal:  J Hematol Oncol       Date:  2018-05-10       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.